Home
About
- Company
- Careers
Technology
Pipeline
Collaboration
News
Investors
Contact

Menu

Home
About
- Company
- Careers
Technology
Pipeline
Collaboration
News
Investors
Contact

Search

Close

中文

Menu

中文

Company

Home > Company

Our Vision
Company Profile
Management Team
Journey & Honors

Menu

Our Vision
Company Profile
Management Team
Journey & Honors

We are committed to leading the development of new drugs for the treatment of genitourinary tumors and other major diseases

Links

Company
Technology
Pipeline
Collaboration
News
Careers
Contact

News

Asieris named “2022 TOP 20 Most Influential Innovative Enterprises in Small Molecule Drugs”
The Oral APL-1202 in Combination with PD-1 inhibitor Tislelizumab as Neoadjuvant Therapy has Entered Phase II Clinical Study
Asieris Obtained IND Approval from US FDA for APL-1401, a New Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris, Completed the First Patient Dose in Phase III Trial
Hexvix®, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance
Asieris Included in the SSE STAR Biology and Medicine Index
Highlights of Asieris 2022 Semi-Annual Report

Contact

info@asieris.com
USA
201 King of Prussia Rd.
Suite 650 Radnor, PA 19087
USA
319 N. Bernardo Ave.
Mountain View, CA 94043
China
8F Building 56
1000 Jinhai Rd
Pudong, Shanghai

Join Us

Partner with us

Copyright © 2014-2022 Asieris Pharmaceuticals. All Rights Reserved.